Moderate-Dose Cannabidiol
Phase 3Small molecule
Moderate-Dose Cannabidiol is one of 23 small molecule programs targeting Generalized Anxiety Disorder. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Generalized Anxiety Disorder
#DrugCompanyPhaseTrials
1Lexapro
AbbVieApproved
Cymbalta
Jazz PharmaceuticalsApproved
Geodon
PfizerApproved
Buspar
Bristol-Myers SquibbApproved
Paxil
SSebela Pharmaceuticals Development LLC
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ativan
BBausch Health Americas, Inc.
Approved
Lunesta
Akero TherapeuticsApproved
Xanax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Zoloft
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Moderate-Dose Cannabidiol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- WWayne State University